Synergy between tumor necrosis factor α and interleukin-1 in the induction of sickness behavior in mice

[1]  R. Dantzer,et al.  Cytokines and Sickness Behavior , 1998, Annals of the New York Academy of Sciences.

[2]  W. Fiers,et al.  Tumor necrosis factor, its receptors and the connection with interleukin 1 and interleukin 6. , 1993, Immunobiology.

[3]  M. Fantino,et al.  Evidence for a direct central anorectic effect of tumor-necrosis-factor-alpha in the rat , 1993, Physiology & Behavior.

[4]  M. Brouns,et al.  Appearance of interleukin-1 in macrophages and in ramified microglia in the brain of endotoxin-treated rats: a pathway for the induction of non-specific symptoms of sickness? , 1992, Brain Research.

[5]  C. Dinarello.  Role of Interleukin‐l in Infectious Diseases , 1992 .

[6]  R. Dantzer,et al.  Interleukin-1 mediates behavioural but not metabolic effects of tumor necrosis factor α in mice , 1991 .

[7]  K. Tracey,et al.  Tumor necrosis factor (cachectin) in the biology of septic shock syndrome. , 1991, Circulatory shock.

[8]  C. Dinarello.  The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrome. , 1991, The Journal of infectious diseases.

[9]  E. Chen,et al.  Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[10]  M. Kluger.  Fever: Role of Pyrogens and Cryogens , 1991, Physiological reviews.

[11]  Robert C. Thompson,et al.  Interleukin-1 receptor antagonist reduces mortality from endotoxin shock , 1990, Nature.

[12]  T. Fahey,et al.  Metabolic effects of cachectin/tumor necrosis factor are modified by site of production. Cachectin/tumor necrosis factor-secreting tumor in skeletal muscle induces chronic cachexia, while implantation in brain induces predominantly acute anorexia. , 1990, The Journal of clinical investigation.

[13]  Robert C. Thompson,et al.  Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor , 1990, Nature.

[14]  L. Moldawer,et al.  Anticachectin/tumor necrosis factor‐α antibodies attenuate development of cachexia in tumor models , 1989, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  N. Rothwell.  Central effects of TNFα on thermogenesis and fever in the rat , 1988, Bioscience reports.

[16]  B. Hart.  Biological basis of the behavior of sick animals , 1988, Neuroscience & Biobehavioral Reviews.

[17]  C. Plata-salamán,et al.  Tumor necrosis factor and interleukin-1β: suppression of food intake by direct action in the central nervous system , 1988, Brain Research.

[18]  C. Dinarello,et al.  Biology of interleukin 1 , 1988, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[19]  J. Vilček,et al.  Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities. , 1987, Laboratory investigation; a journal of technical methods and pathology.

[20]  L. Chess,et al.  Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1 , 1986, The Journal of experimental medicine.

[21]  B. Beutler,et al.  Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1 , 1986, The Journal of experimental medicine.

[22]  I. Fidler,et al.  Natural and recombinant human interleukin 1-beta is cytotoxic for human melanoma cells. , 1986, Journal of immunology.

[23]  D. Stern,et al.  Modulation of endothelial cell hemostatic properties by tumor necrosis factor , 1986, The Journal of experimental medicine.

[24]  B. Aggarwal,et al.  Human interleukin 1 is a cytocidal factor for several tumor cell lines. , 1985, Journal of immunology.

[25]  R. Cotran,et al.  Interleukin-1 activation of vascular endothelium. Effects on procoagulant activity and leukocyte adhesion. , 1985, The American journal of pathology.

[26]  J. Gamble,et al.  Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[27]  L. Old,et al.  Tumor necrosis factor (TNF). , 1985, Science.

[28]  K. Onozaki,et al.  Role of interleukin 1 in promoting human monocyte-mediated tumor cytotoxicity. , 1985, Journal of immunology.

[29]  B. Beutler,et al.  Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells , 1985, The Journal of experimental medicine.

[30]  R. Cotran,et al.  Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells , 1984, The Journal of experimental medicine.

[31]  C. Grunfeld,et al.  Pathophysiology of the AIDS wasting syndrome. , 1992, AIDS clinical review.

[32]  L. Tartaglia,et al.  Two TNF receptors. , 1992, Immunology today.

[33]  R. Dantzer,et al.  Interleukin-1 receptor antagonist blocks effects of IL-1α and IL-1β on social behaviour and body weight in mice , 1991 .

[34]  B. Beutler,et al.  Tumor necrosis, cachexia, shock, and inflammation: a common mediator. , 1988, Annual review of biochemistry.

[35]  B. Beutler,et al.  The role of cachectin/TNF in endotoxic shock and cachexia. , 1988, Immunology today.